215 related articles for article (PubMed ID: 9334622)
1. The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients.
Noordzij MA; Bogdanowicz JF; van Krimpen C; van der Kwast TH; van Steenbrugge GJ
J Urol; 1997 Nov; 158(5):1880-4; discussion 1884-5. PubMed ID: 9334622
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
3. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy.
Krijnen JL; Bogdanowicz JF; Seldenrijk CA; Mulder PG; van der Kwast TH
J Urol; 1997 Jul; 158(1):171-4. PubMed ID: 9186347
[TBL] [Abstract][Full Text] [Related]
5. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
7. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy.
Ferguson J; Zincke H; Ellison E; Bergstrahl E; Bostwick DG
Urology; 1994 Jul; 44(1):91-5. PubMed ID: 8042266
[TBL] [Abstract][Full Text] [Related]
8. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
9. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.
Di Lorenzo G; De Placido S; Autorino R; De Laurentiis M; Mignogna C; D'Armiento M; Tortora G; De Rosa G; D'Armiento M; De Sio M; Bianco AR; D'Armiento FP
Prostate Cancer Prostatic Dis; 2005; 8(1):54-9. PubMed ID: 15655565
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation.
Matsuura H; Hayashi N; Kawamura J; Shiraishi T; Yatani R
Eur Urol; 2000 Feb; 37(2):212-7. PubMed ID: 10705201
[TBL] [Abstract][Full Text] [Related]
11. Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma.
Anvari K; Seilanian Toussi M; Kalantari M; Naseri S; Karimi Shahri M; Ahmadnia H; Katebi M; Sedighi Pashaki A; Dayani M; Broumand M
Urol J; 2012; 9(1):381-8. PubMed ID: 22395836
[TBL] [Abstract][Full Text] [Related]
12. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.
Mori R; Dorff TB; Xiong S; Tarabolous CJ; Ye W; Groshen S; Danenberg KD; Danenberg PV; Pinski JK
Prostate; 2010 Nov; 70(15):1692-700. PubMed ID: 20564320
[TBL] [Abstract][Full Text] [Related]
13. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
[TBL] [Abstract][Full Text] [Related]
14. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
17. Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations.
Schäfer W; Funke PJ; Kunde D; Rausch U; Wennemuth G; Stützer H
J Urol; 2006 Aug; 176(2):532-7. PubMed ID: 16813883
[TBL] [Abstract][Full Text] [Related]
18. The worst histologic elements predict prognosis in moderately-differentiated prostate cancer patients with androgen-withdrawal endocrine therapy.
Masuda M; Iki M; Noguchi S; Mikata K; Kubota Y; Harada M; Hosaka M
Eur Urol; 1999 Sep; 36(3):197-202. PubMed ID: 10450002
[TBL] [Abstract][Full Text] [Related]
19. Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome.
Zagars GK; Sands ME; Pollack A; von Eschenbach AC
J Urol; 1994 May; 151(5):1330-3. PubMed ID: 7512663
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
